Equity Components [Axis] Common Stock [Member] Additional Paid-in Capital [Member] Retained Earnings [Member] AOCI Attributable to Parent [Member] Currency [Axis] United States of America, Dollars United Kingdom, Pounds Euro Member Countries, Euro Award Type [Axis] Warrants [Member] Stock Options [Member] Fair Value Hierarchy and NAV [Axis] Fair Value, Inputs, Level 1 [Member] Fair Value, Inputs, Level 2 [Member] Fair Value, Inputs, Level 3 [Member] Fair Value, Inputs, Level 1, Level 2, and Level 3 [Member] Finite-Lived Intangible Assets by Major Class [Axis] Patents [Member] Computer Software, Intangible Asset [Member] Warrant [Member] Debt Instrument [Axis] Note Purchase Agreement 1 [Member] Note Purchase Agreement 2 [Member] Note Purchase Agreement 3 [Member] Long-Term Debt, Type [Axis] Secured Note [Member] Related Party, Type [Axis] Investor [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Geographical [Axis] UNITED STATES UNITED KINGDOM Legal Entity [Axis] Armistice Capital L L C And Alyeska Master Fund L L C [Member] Market Offering Agreement [Member] H C Wainwright And Co L L C [Member] At The Marketoffering Agreement [Member] Tiger Trading Partners L L C [Member] Tiger Management L L C [Member] A T M Facility 2021 [Member] Title of Individual [Axis] Board Of Directors [Member] Derivative Instrument [Axis] Equity Option [Member] Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] ICFR Auditor Attestation Flag Document Financial Statement Error Correction [Flag] Auditor Firm ID Auditor Name Auditor Location Statement of Financial Position [Abstract] ASSETS Current assets: Cash Inventory, net Prepaid expenses and other current assets VAT receivable Deposit on foreign exchange contract Receivable from related parties Total current assets Property and equipment, net of accumulated depreciation Intangible assets, net of accumulated amortization Total assets Current liabilities: Accounts payable Accrued expenses and other liabilities Notes payable, current portion Payable to related parties Deferred revenue, current portion Foreign exchange contract derivative liability Warrant liability Total current liabilities Notes payable, non-current portion Deferred revenue, non-current portion Total liabilities Commitments and contingencies Stockholders’ equity (deficit): Common stock, par value $0.001 – authorized: 42,000,000 shares; issued and outstanding: 28,899,402 and 24,102,866 as of March 31, 2023 and 2022, respectively Additional paid-in capital Accumulated deficit Accumulated other comprehensive (loss) income Total stockholders’ equity (deficit) Total liabilities and stockholders’ equity (deficit) Common stock, par value per share Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Income Statement [Abstract] Sales Cost of sales Cost of sales-inventory write down Gross profit (loss) Operating expenses: Research and development General and administrative Impairment of intangible assets Total operating expenses Loss from operations Interest expense Change in fair value of warrant liability Loss before income tax benefit Provision for income tax benefit Net loss Other comprehensive income: Foreign currency translation adjustment Comprehensive loss Earnings per share, basic Earnings per share, diluted Weighted average number of shares outstanding, basic Weighted average number of shares outstanding, diluted Statement [Table] Statement [Line Items] Beginning balance, value Beginning Balance, Shares Issuance of common shares, net of costs Issuance of common shares, net of costs, shares Fair value of warrant liability recognized in connection with issuance of common shares Issuance of common shares, net of costs of $50,765 Issuance of common shares, net of costs, shares Exercise of warrants Exercise of warrants, Shares Restricted shares issued as stock-based compensation Restricted shares issued as stock-based compensation, Shares Options issued to directors Foreign currency translation adjustment Net loss Ending balance, value Ending Balance, Shares Statement of Stockholders' Equity [Abstract] Issuance of common shares net of costs Statement of Cash Flows [Abstract] Cash Flows from Operating Activities: Net loss Adjustments to reconcile net loss to net cash used in operating activities: Depreciation and amortization Accretion of debt discount Monitoring fee interest expense added to notes payable Fees for note amendments expense added to note payable Inventory write-down Impairment of intangible assets Change in fair value of foreign exchange contract derivative liability Change in fair value of warrant liability Stock-based compensation Changes in operating assets and liabilities: Inventory Prepaid expenses and VAT receivable Deposit on foreign exchange contract Accounts payable Accrued expenses and other liabilities Receivable/payable to related parties Deferred revenue Net cash used in operating activities Cash Flows from Investing Activities: Purchase of property and equipment Capitalized patent costs Capitalized software development costs Net cash used in investing activities Cash Flows from Financing Activities: Proceeds from issuance of common shares Costs incurred in relation to equity financing Proceeds from warrant exercise Proceeds from issuance of long term debt, net of discount Repayments of notes payable Net cash (used in) provided by financing activities Net decrease in cash Effect of exchange rate changes on cash Cash at beginning of year Cash at end of year Supplemental cash flow information: Interest paid Taxes paid Supplemental disclosure of non-cash financing activities: Fair value of warrant liability recognized in connection with issuance of common shares Monitoring fees added to notes payable Accounting Policies [Abstract] ORGANIZATION, PRINCIPAL ACTIVITIES AND MANAGEMENT’S PLANS BASIS OF PRESENTATION SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Commitments and Contingencies Disclosure [Abstract] LICENSING AGREEMENT Inventory Disclosure [Abstract] INVENTORY Property, Plant and Equipment [Abstract] PROPERTY AND EQUIPMENT Goodwill and Intangible Assets Disclosure [Abstract] INTANGIBLE ASSETS Derivative Instruments and Hedging Activities Disclosure [Abstract] DERIVATIVE LIABILITIES Debt Disclosure [Abstract] NOTES PAYABLE Related Party Transactions [Abstract] RELATED PARTY TRANSACTIONS Income Tax Disclosure [Abstract] INCOME TAXES Equity [Abstract] STOCKHOLDERS’ EQUITY Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract] CONTINGENCIES Subsequent Events [Abstract] SUBSEQUENT EVENTS Use of estimates Revenue recognition Deferred revenue Research and development expenses Cash and cash equivalents Inventory Property and equipment Intangible assets Software development costs Income taxes Earnings (loss) per share Foreign currency translation Derivative Financial Instruments Fair value of financial instruments Retirement benefit plan Stock-based compensation Direct costs incurred for equity offerings Reclassifications Recent accounting pronouncements Schedule of disaggregates cash balances by currency denomination Schedule of common stock underlying outstanding options Schedule of exchange rates translate amounts Schedule of assets and liabilities at fair value Schedule of warrant derivative liability measured at fair value on a recurring basis Schedule of inventory Schedule of property and equipment Schedule of Intangible Assets Reclassification out of Accumulated Other Comprehensive Income [Table] Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items] Schedule of warrant liability Schedule of fair value of the foreign currency contract liability Schedule of notes payable Schedule of related party transactions Schedule of loss before income tax Reconciliation of effective tax rate Schedule of deferred income tax assets Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Line Items] Schedule of option award activity Schedule of key assumptions Total cash and cash equivalents Net loss Cash in operations Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Warrant outstanding Foreign currency exchange rates Foreign currency average exchange rates Platform Operator, Crypto-Asset [Table] Platform Operator, Crypto-Asset [Line Items] Total assets Foreign exchange contract liability Warrant derivative liability Total liabilities Warrant derivative liability, beginning balance Fair value of warrant derivative liability recognized upon issuance of warrants Gain on change in fair value of warrant derivative liability Warrant derivative liability, ending balance Software develpoment costs Unrecognized tax benefits Retirement benefit plan expenses VAT receivable Prepaid expenses and other receivables Prepaid expenses balance Non refundable, upfront cash payment Non-refundable, upfront cash payment Deferred Revenue Raw materials Finished products Total Write down of inventory Plant and machinery Furniture and fixtures Property and equipment gross Less Accumulated Depreciation Net Book Value Depreciation expense Schedule of Finite-Lived Intangible Assets [Table] Finite-Lived Intangible Assets [Line Items] Patents and licenses Less accumulated amortization Less impairment Intangible assets, gross Intangible assets net Amortization expense related to intangible assets Intangible assets impairment Risk-free interest rate Expected volatility Expected life (in years) Expected dividend yield Warrant liability Notional amount Leveraged amount (used to determine fair value of contract liability) Expected remaining term (in months) Foreign currency contract liability Warrants issued Volatility interest rate Leveraged amount Contractual notional amount Description of conversion terms for debt instrument Leverage leveraged amount Schedule of Short-Term Debt [Table] Short-Term Debt [Line Items] Balance of notes payable, net of note discounts Total notes payable Unamortized debt discount Long term debt, Current portion Long term debt, Non-current portion Schedule of Long-Term Debt Instruments [Table] Debt Instrument [Line Items] Principal amount Maturity date Cash proceeds Debt discount Debt discount amortized Commissions paid Transaction expenses Interest rate Debt instrument periodic payment Debt instrument increased periodic payment Aggregate fees fair value of debt Carrying amount of old debt Debt instruments fees Extinguishment debt Due (to)/from related parties at beginning of year Amounts invoiced by Pharma to DDL, NM and TCL primarily relating to research and development expenses Amounts invoiced by DDL to Pharma Amounts invoiced by DDL to Pharma Amounts repaid by DDL to Pharma Foreign exchange differences Foreign exchange differences Due (to)/from related parties at end of year Loss before income taxes arising in UK Loss before income taxes arising in U.S. Total loss before income tax benefit Loss before income taxes Expected tax benefit Expected tax benefit, Percentage Foreign tax differential Foreign tax differential, Percentage Enhanced research and development Enhanced research and development, Percentage Prior year true up of nol Prior year true up of nol, Percentage Other Other, Percentage Change in valuation allowance Change in valuation allowance, Percentage R&D credit received R&D credit received, Percentage Actual income tax benefit Income tax benefit, Percentage Net operating tax loss carried forward Research and development enhancement Other items Valuation allowance Net deferred tax assets Income tax rate HMRC tax credit Net operating losses Research and development Offsetting Assets [Table] Offsetting Assets [Line Items] Number of Options, Outstanding beginning Weighted Average Exercise Price, Outstanding beginning Number of Options, Granted Weighted Average Exercise Price, Granted Number of Options, Exercised Weighted Average Exercise Price, Exercised Number of Options, Forfeited Weighted Average Exercise Price, Forfeited Number of Options, Expired Weighted Average Exercise Price, Exercised Weight Average remaining Contractual Term (years) Number of Options, Outstanding ending Weighted Average Exercise Price, Outstanding ending Number of Options, Vested and exercisable Weighted Average Exercise Price, Vested and exercisable Weight Average remaining Contractual Term (years), Vested and exercisable Stock Price Exercise Price Term Volatility Discount Rate (Bond Equivalent Yield) Weight Average remaining Contractual Term (years) exercised Weight Average remaining Contractual Term (years) granted Weighted Average Exercise Price, Expired Weighted Average Exercise Price Vested and exercisable Aggregate amount Number of shares purchased Exercise price Exercise price Gross proceeds total Costs deducted in relation to equity financing Aggregate shares price value Number of common stock sold Sale of Stock, Price Per Share Gross proceeds Sale of stock Options granted Fair value of stock options Assets, Current Assets Liabilities, Current Liabilities Equity, Attributable to Parent Liabilities and Equity Cost of Goods and Services Sold CostOfSalesinventoryWriteDown Gross Profit Operating Expenses Operating Income (Loss) Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Income Tax Expense (Benefit) Comprehensive Income (Loss), Net of Tax, Attributable to Parent Shares, Outstanding OCI, Foreign Currency Transaction and Translation Gain (Loss), Arising During Period, Tax Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Impairment of Intangible Assets (Excluding Goodwill) ChangesInFairValueOfWarrantLiability Increase (Decrease) in Inventories Increase (Decrease) in Prepaid Expense and Other Assets DepositOnForeignExchangeContracts Increase (Decrease) in Accounts Payable Increase (Decrease) in Accounts Payable and Accrued Liabilities Increase (Decrease) in Accounts Receivable, Related Parties Net Cash Provided by (Used in) Operating Activities Payments to Acquire Property, Plant, and Equipment Payments to Acquire Intangible Assets Payments to Develop Software Net Cash Provided by (Used in) Investing Activities CostsIncurredInRelationToEquityFinancing Repayments of Notes Payable Net Cash Provided by (Used in) Financing Activities Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents FairValueOfWarrantLiabilityRecognizedInConnectionWithIssuanceOfCommonShares DeferredRevenuePolicyTextBlock StockbasedCompensationPolicyTextBlock WarrantDerivativeLiability GainOnChangeInFairValueOfWarrantDerivativeLiability Value Added Tax Receivable Property, Plant and Equipment, Gross Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Finite-Lived Intangible Assets, Accumulated Amortization Fair Value Adjustment of Warrants Long-Term Debt, Current Maturities RelatedPartyTransactionDueFromToRelatedParties AmountsRepaidByDdlToPharma Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount Deferred Tax Assets, Valuation Allowance Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price